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INTRODUCTION
Distinction between mesothelial proliferations (hyperplasia
or mesothelioma) and metastatic carcinomas, especially adeno-
carcinomas has been one of the most difficult problems in
cytology as well as in surgical pathology. Various histochemi-
cal and immunohistochemical stains have been applied to solve
this problem, as adjuncts to morphologic differential features
including ultrastructural findings. Recently, several new anti-
bodies including cadherins and cytokeratin subtypes have been
reported to be useful in differential diagnosis between meso-
thelial proliferation and metastatic adenocarcinoma (1-6).
Cadherins are a multi-gene family of transmembrane glyco-
proteins and play an important role in sorting cells into spe-
cialized tissues during morphogenesis (7). E-cadherin (E-
CD) exists in the adherence junctions of epithelium, medi-
ating tight cell-to-cell adhesion, and is expressed by almost
all kinds of epithelial cells (8). Although cadherin expression
may be altered in tumorigenesis, there is an indication that
their expression, predominantly localized at the lateral cell
borders, may be useful in tracing the histogenetic origin of
tumors. Particularly, E-CD has been suggested as a useful
marker for distinguishing adenocarcinoma from mesothe-
lioma (1, 9). E-CD was strongly and diffusely expressed in
most cases of carcinomas (20-40%) while it was weakly and
focally expressed in neoplastic or reactive mesothelial prolif-
eration (0-6%) (1, 2, 5, 10). 
Cytokeratin (CK) filaments are the intermediate filaments
forming the skeleton of epithelial cells, providing support to
maintain cell integrity and the structure of epithelial tissues.
Human epithelia can present 20 different types of CKs (11).
Not a single CK subtype, but a panel of CK subtypes, which
includes both positive and negative markers for mesothelial
cells, should be employed for distinguishing mesothelioma
from adenocarcinomas. The expression of pan CK, in con-
trast to that of E-CD, does not clearly indicates the presence
of carcinoma cells in effusion because mesothelial cells express
a broad range of CKs (12). CK5/6 is one of the positive mark-
ers for mesothelial proliferation (mesothelioma) with high
sensitivity (80-100%) and sufficient specificity for practical
use in distinguishing it from metastatic adenocarcinomas (4,
13). High molecular weight CK (34bE12), composed of CKs
1, 5, 10 and 14, labels reactive and neoplastic mesothelial cells,
basal cells, and squamous, ductal and complex epithelia (14-
16). The tissue distribution of CK17 appears to be relatively
limited to certain myoepithelial and basal cells of complex
epithelia, and subsets of hair shaft epithelia (17). Therefore,
the investigation of the utility of CK17 as a potential differ-
ential marker seems to be worthwhile.
In this study, expression of E-CD and several cytokeratin
subtypes was investigated in a variety of carcinomas and meso-
theliomas using cellblock sections from effusion specimens,
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E-cadherin and Cytokeratin Subtype Profiling in Effusion Cytology
Diagnostic utility of E-cadherin (E-CD) and cytokeratin (CK) subtype profiling in effu-
sion cytology was investigated, employing immunocytochemistry on cellblock sec-
tions available from 211 metastatic carcinomas (MC), 6 mesotheliomas and 73 reac-
tive mesothelial hyperplasias (MH). E-CD and monoclonal carcinoembryonic anti-
gen (mCEA) stained 85% (120/141) and 65% (138/211) of MC, respectively. E-CD
staining of MC was frequently heterogeneous (76/120) and absent in all anaplastic
carcinomas (0/2). E-CD stained none (0/57) of MH while mCEA and epithelial mem-
brane antigen (EMA) stained 12% (9/73) and 32% (16/32) of MH, respectively. Of
6 mesotheliomas, E-CD focally stained in 2 while mCEA stained none and EMA
stained all. CK20 and CK17 stained none of MH or mesotheliomas. CK20 stained
15% of MC and CK 17 stained 22% of MC. CK5/6 and high molecular weight CK
stained all mesotheliomas, 56% and 88% of MH, 26% and 39% of MC, respectively.
MC showed predominant CK7+/20-expression, with the exceptions of MC from muci-
nous type of colon/rectum and ovary showing predominant CK20 positive. E-CD
may be a useful positive marker for MC in effusion cytology, although it may focally
stain in some mesotheliomas. Any positive staining for CK20 of MC suggests MC
from the gastrointestinal tract or ovary among others.
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Cytokeratin 20; Keratin 7
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and was compared to the expression of monoclonal carcinoem-
bryonic antigen (mCEA) and epithelial membrane antigen
(EMA).
MATERIALS AND METHODS
The cytological materials of malignant effusion and meso-
thelial hyperplasia available formalin-fixed and paraffin-em-
bedded effusion cellblocks were included in this study dur-
ing 3 yr from 1997 to 1999 in daily routine sign-out in Sam-
sung Seoul Hospital. Two hundred and eleven cases of meta-
static carcinoma, 6 cases of mesothelioma and 73 cases of
reactive mesothelial hyperplasia were selected for this study.
Hematoxylin-eosin (H&E) stained smears, Papanicolau stained
smears, H&E stained cellblock sections, and available tissue
sections of all cases were reviewed.
The metastatic carcinomas consisted of anaplastic carcino-
ma (4 cases) from the ovary (1 case), pancreas (1 case), thyroid
(1 case) and unknown primary site (1 case); adenocarcinoma
(186 cases) from the Ampulla of Vater (1 case), bile duct (12
cases), breast (16 cases), colon/rectum (13 cases), endometrium
(7 cases), lung (30 cases), ovary (38 cases), pancreas (8 cases),
stomach (55 cases), and thyroid (1 case); adenosquamous car-
cinomas (3 cases) from the ovary (1 case), pancreas (1 case),
and thyroid (1 case); hepatocellular carcinomas (2 cases); small
cell carcinomas from the lung (5 cases); and squamous cell
carcinomas (10 cases) from the esophagus (4 cases), lung (3
cases), and uterine cervix (3 cases). Adenocarcinomas from
the breast consisted of ductal type (7 cases), lobular type (3
cases) and not otherwise specified (6 cases). Adenocarcinomas
from the ovary consisted of mucinous (2 cases) and non-muci-
nous carcinoma (26 cases).
Immunohistochemical staining was performed in consec-
utive unstained sections taken from each cellblock, employ-
ing the avidin-biotin peroxidase complex method (DAKO
LSAB kit-peroxidase, DAKO corp. Denmark) using several
monoclonal  antibodies summarized in Table 1. Not all cases
had been stained with all antibodies because cellblocks were
too thin to yield enough number of sections and a few sec-
tions were rejected on the unavailability of carcinoma cells
and/or technical grounds. Cells were considered positive if
at least one intact cell showed an unequivocal intercellular
membranous staining for E-CD, cytoplasmic and membra-
nous staining for all CK subtypes and EMA, and cytoplas-
mic staining for mCEA. The denominators of the fractions
given show the numbers of cases assessed for each antibody.
RESULTS
Comparison of E-CD with mCEA and EMA as a marker
for carcinoma 
Antibody Clone Dilution and pretreatment Source
E-cadherin 4A2C7 1:80, MW Zymed
Cytokeratin 5/6 1:50, E Roche
Cytokeratin 17 E3 1:50, MW, E DAKO
High M.W. cytokeratin 34bE12 1:80, MW DAKO
Monoclonal CEA II-7 1:100, MW DAKO
EMA E29 1:50, MW DAKO
Cytokeratin 7 OV-TL12/30 1:100, MW, E DAKO
Cytokeratin 20 Ks20.8 1:100, MW, E DAKO
Cytokeratin 19 RCK108 1:50, MW, E DAKO
Cytokeratin 8 35BH11 1:50 MW, E DAKO
Table 1. Antibodies used in this study
f, focal positive; ND, not done; *7 cases out of 7 cases of ductal carcinoma and one case of mammary adenocarcinoma, not otherwise specified; **one
case of mucinous, 19 cases of non-mucinous and 3 cases of adenocarcinoma, not otherwise specified, out of one case of mucinous, 21 cases of non-
mucinous and 3 cases of adenocarcinoma, not otherwise specified.
E-cadherin mCEA EMA
Reactive mesothelial hyperplasia 0/57 (0%) 9 (3+6f)/73 (12%) 16 (1+15f)/50 (32%)
Mesothelioma 2f/6 (33%) 0/6 (0%) 6/6 (100%)
Carcinoma 118 (46+71f)/141 (86%) 138/211 (65%) 58/60 (97%)
Anaplastic carcinoma 0/2 (0%) 0/4 (0%) 1/2 (50%)
Adenocarcinoma 107 (43+64f)/123 (87%) 126/186 (68%) 55/55 (100%)
Ampulla of Vater 0/1 (0%) 1/1 (100%) ND
Bile duct 7 (5+2f)/7 (100%) 7/12 (58%) 6/6 (100%)
Breast 7f/8* (88%) 9/16 (56%) 2/2 (100%)
Colon/rectum 8 (2+6f)/10 (80%) 11/13 (85%) 3/3 (100%)
Endometrium 4 (1+3f)/4 (100%) 1/7 (14%) 2/2 (100%)
Lung 21 (13+8f)/21 (95%) 24/30 (80%) 11/11 (100%)
Ovary 23 (8+15f)/25** (92%) 14/38 (37%) 8/8 (100%)
Pancreas 2f/3 (67%) 7/8 (88%) 2/2 (100%)
Stomach 26 (5+21f)/34 (76%) 51/55 (93%) 10/10 (100%)
Thyroid 1/1 (100%) 1/3 (33%) 1/1 (100%)
Table 2. E-cadherin, monoclonal CEA and epithelial membrane antigen expression in effusion cellblock
CEA, carcinoembryonic antigen; M.W., molecular weight; EMA, epithe-
lial membrane antigen; MW, microwave pretreatment; E, enzyme pre-
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Metastatic carcinoma, with the exception of anaplastic car-
cinoma, were positive for E-CD, mCEA and EMA (Table 2).
E-CD stained 120 out of 141 cases of metastatic carcinoma
(85%), which included the majority cases of adenocarcinoma
(87%) and squamous cell carcinoma (83%). Adenosquamous
carcinoma (2/2), hepatocellular carcinoma (1/1) and small cell
carcinoma (2/3) show also positive for E-CD. E-CD stained
adenocarcinomas from various primary sites, such as bile duct,
breast (all ductal type), colon/rectum, endometrium, lung,
pancreas, stomach, and thyroid. In addition, ovarian adenocar-
cinomas, both mucinous (1/1) and 90% non-mucinous types
(19/21); serous adenocarcinoma (16/17), endometrioid adeno-
carcinoma (2/2), undifferentiated carcinoma (1/2), which are
often difficult to be differentiated from mesothelioma, showed
Fig. 1. E-CD staining in metastatic adenocarcinoma (×400): metastatic papillary serous carcinoma of the ovary exhibits typical intercel-
lular staining (A). Metastatic pulmonary adenocarcinoma exhibits a somewhat heterogeneous staining (B) or a partial loss of staining (C).
Metastatic adenocarcinoma from common bile duct exhibits rather exaggerated, cytoplasmic staining (D). Metastatic signet ring cell car-
cinoma (arrows) of the colon Inset: cytoplasmic mucin in tumor cells, H&E (E) and metastatic undifferentiated carcinoma (arrows) of the
ovary (F) exhibit none. Note many inflammatory cells are in background.
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diffuse E-CD expression in the majority cases (Fig. 1A).
In 76 out of 120 cases (63%) of carcinomas showing E-CD
expression, E-CD stain was focal and/or weak with hetero-
geneous pattern among carcinoma cells from the same case,
particularly when they were singly dissociated (Fig. 1B, C).
Infrequently, E-CD stain appeared exaggerated or altered in
cytoplasmic staining (Fig. 1D). About 15% of metastatic car-
cinomas, including all anaplastic carcinomas, undifferentiat-
ed and signet ring cell carcinoma, showed no expression of
E-CD (Fig. 1E, F).
Compared to E-CD, mCEA infrequently stained adenocar-
cinomas from the endometrium, thyroid, and ovary. mCEA
also stained small cell carcinomas less frequently than E-CD.
Compared to E-CD, EMA was more sensitive, but a much
less specific positive marker for metastatic carcinoma. EMA
stained all cases of metastatic carcinoma. 
E-CD stained none of reactive mesothelial hyperplasias (0/
57) (Fig. 2A) while mCEA and EMA stained 12% and 32%
of reactive mesothelial hyperplasias, respectively. E-CD also
stained 2 out of 6 cases of mesothelioma (30%), with focal
membranous pattern (Fig. 2B, C) while mCEA stained none
(0%), and EMA stained all cases (100%). 
Immunoreactivity for cytokeratin subtypes 
Cytokeratins 19, 8, and 7 showed similar pattern of expres-
sion (Table 3). All three subtypes stained most cases of reactive
mesothelial hyperplasia, ranging from 86 to 93%, and all
cases of mesotheliomas (100%). CK19, CK8, and CK7 stained
a variety of metastatic carcinomas, but with variable percent-
ages (82%, 49%, and 81%, respectively). 
CK 20 stained none of the reactive mesothelial hyperplasias
and mesotheliomas  while it stained about 15% of metastat-
ic carcinomas, which were limited to metastatic adenocarci-
nomas originated from the colon/rectum (8/13), lung (1/30),
ovary (4/38) (Fig. 3A), and stomach (17/55) (Fig. 3B), and
metastatic hepatocellular carcinomas (1/3). Similarly, CK 17
stained none of the reactive mesothelial hyperplasias or meso-
CK, cytokeratin; HCK, high molecular weight cytokeratin; ND, not done. *3 cases of ductal carcinoma out of 7 cases of ductal carcinoma, 3 cases of
lobular carcinoma and 2 cases of adenocarcinoma, not otherwise specified.
CK19 CK8 CK7 CK20 CK17 CK5/6 HCK
Reactive mesothelial hyperplasia 68/73 (93%) 65/73 (89%) 63/73 (86%) 0/73 (0%) 0/73 (0%) 41/73 (56%) 64/73 (88%)
Mesothelioma 6/6 (100%) 6/6 (100%) 6/6 (100%) 0/6 (0%) 0/6 (0%) 6/6 (100%) 6/6 (100%)
Carcinoma 167/205 (81%) 101/207 (49%) 170/207 (82%) 31/207 (15%) 46/207 (22%) 54/206 (26%) 81/207 (39%)
Anaplastic carcinoma 2/4 (50%) 1/4 (25%) 4/4 (100%) 0/4 (0%) 0/4 (0%) 0/4 (0%) 0/4 (0%)
Adenocarcinoma 152/183 (83%) 94/183 (51%) 152/183 (83%) 30/183 (16%) 39/183 (21%) 46/183 (25%) 69/183 (37%)
Bile duct 12/12 (100%) 12/12 (100%) 12/12 (100%) 0/12 (0%) 6/12 (50%) 6/12 (50%) 6/12 (50%)
Breast 10/12 (83%) 6/12 (50%) 10/12 (83%) 0/12 (0%) 3/12* (25%) 3/12 (25%) 7/12 (58%)
Colon/rectum 9/13 (69%) 3/13 (23%) 0/13 (0%) 8/13 (62%) 0/13 (0%) 0/13 (0%) 5/13 (38%)
Endometrium 4/7 (56%) 4/7 (56%) 7/7 (100%) 0/7 (0%) 2/7 (29%) 3/7 (43%) 4/7 (57%)
Lung 28/30 (93%) 10/30 (33%) 30/30 (100%) 1/30 (3%) 3/30 (10%) 13/30 (43%) 16/30 (53%)
Ovary 35/38 (92%) 27/38 (71%) 36/38 (95%) 4/38 (10%) 12/38 (32%) 15/38 (39%) 17/38 (45%)
Pancreas 8/8 (100%) 5/8 (63%) 7/8 (88%) 0/8 (0%) 3/8 (38%) 0/8 (0%) 0/8 (0%)
Stomach 42/55 (76%) 26/55 (47%) 37/55 (67%) 17/55 (31%) 10/55 (18%) 5/55 (9%) 14/55 (25%)
Thyroid 3/3 (100%) 1/3 (33%) 3/3 (100%) 0/3 (0%) 0/3 (0%) 0/3 (0%) 0/3 (0%)
Table 3. Expression of cytokeratin subtypes in effusion cellblocks
Fig. 2. E-CD staining in mesothelial cells: reactive mesothelial cells exhibit none (A, ×400) and neoplastic mesothelial cells (arrow) (B, ×400). 
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theliomas (Fig. 4A) while it stained about 22% of metastatic
carcinomas, including metastatic adenocarcinomas originat-
ed from the bile duct (6/12), breast (all ductal type, 3/12)
(Fig. 4B), endometrium (2/7), lung (3/30), ovary (12/38), pan-
creas (3/8), and stomach (10/55), and metastatic squamous
cell carcinomas (4/10) (Fig. 4C). 
Both CK5/6 and high molecular weight keratin (HCK)
stained most cases of reactive mesothelial hyperplasia (56%
and 88%, respectively) and all 6 cases of mesothelioma (Fig.
5A), while they stained smaller portion of metastatic carci-
nomas (26% and 39%, respectively), which included adeno-
carcinoma from bile duct, breast, endometrium, lung, ovary
and stomach. Notably, both CK5/6 and HCK stained meta-
static carcinomas with squamous differentiation, such as ade-
nosquamous cell carcinoma and squamous cell carcinoma
(Fig. 5B).
Fig. 3. Metastatic ovarian mucinous carcinoma (A, ×400) and metastatic gastric signet ring cell carcinoma (B, ×400) show diffuse mem-
branous staining for CK20. 
A B
Fig. 4. Mesothelial cells exhibit none of stain for CK17 (A, ×400).
In contrast, metastatic mammary duct carcinoma (B, ×200) and
metastatic esophageal squamous cell carcinoma (C, ×400) exhibit
diffuse membranous/cytoplasmic staining for CK17.
A B
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Combined CK7/20 profile
Mesotheliomas and metastatic adenocarcinomas from the
bile duct, breast, endometrium, lung, ovary (all non-mucinous
type), pancreas and thyroid showed predominant CK7+/20-
expression. Metastatic adenocarcinomas from the colon/rec-
tum showed predominant CK7-/CK20+. Metastatic ade-
nocarcinomas from the stomach showed all four profiles with
slight predominance of CK7+/20-. Four cases of metastatic
adenocarcinoma from the ovary with CK7+/CK20+ were
all of the mucinous type.
DISCUSSION
The present study showed that E-cadherin was useful for
distinguishing carcinoma cells from both reactive and neo-
plastic mesothelial cells in effusion cytology. In previous stud-
ies employing tissue sections, E-CD stained most of the pul-
monary, breast duct (not lobular), ovary, colon, thyroid and
prostate adenocarcinomas while it stained only about 6% of
the mesotheliomas, with relatively weak and focal reactivity,
suggesting that E-cadherin may be a useful marker in the
differential diagnosis between epithelial mesotheliomas and
adenocarcinomas of various origin (1, 2, 5, 9). In contrast, the
study by Simsir et al. (10), which revealed E-CD expression
in 12 out of 26 cases of mesothelioma on cellblock sections,
suggested that E-CD might not useful in the differentiation
of adenocarcinoma cells from neoplastic mesothelial cells as
much as from reactive mesothelial cells. 
The previous result reported immunoreactivity of CEA,
EMA, E-CD, N-CD, and CK5/6, shows similar results with
our ones: E-CD stained all cases of peritoneal or ovarian serous
carcinomas, which mCEA rarely stained (18). E-CD reactiv-
ity in mesothelioma was limited to a few cases while EMA
strongly stained all. 
The results showing E-CD negative staining in about 15%
of carcinoma including anaplastic type, its focal positive stain-
ing in about 50% of mesothelioma, and its frequent hetero-
geneous reactivity in the same carcinoma, may represent not
only some limitations of E-CD in terms of diagnostic utility,
by being the potential sources of false positive/negative results,
but also some pathological implication of E-CD expression.
As the previous studies revealed, decreased E-cadherin expres-
sion in carcinomas, resulting to a heterogeneous reactivity
or complete negativity immunohistochemically, seemed to
correlate with cellular dedifferentiation/anaplasia, and disin-
tegration of carcinoma cell nests, frequently leading to cyto-
logically dissociated single cells (19, 20). The observation that
E-CD stained carcinoma cells focally and/or weakly with a
heterogeneous pattern in more than half of cases might be
related to the fact that this study employed cases with relative-
ly high tumor stage, presenting with the malignant effusion.
E-cadherin is thought to be indispensable for the forma-
tion and maintenance of carcinoma cell nests such as the glan-
dular differentiation of colorectal tumor cells, just as it is
indispensable for the formation and maintenance of normal
epithelial tissues (21). E-cadherin loss or dysfunction has been
described in a variety of human and experimental neoplasms,
and correlated with increased tumor stage and decreased
patient survival, with only a few exceptions (22-24). It has
been thought that E-cadherin loss or dysfunction, probably
resulting from down regulation or mutation of cadherin genes
during tumorigenesis, causes loss of cell-to-cell adhesion in
carcinoma cell clusters, which leads to increased invasiveness
of carcinoma cells (26). The intact E-cadherin is considered
as a suppressor of invasion (27). 
Focal E-CD stain in mesotheliomas might be related with
papillary architecture of mesothelioma. In a study regarding
E-CD overexpression in papillary urothelial carcinoma, it has
been suggested that papillary structure may be one of the archi-
tectures requiring the strongest intercellular adhesion medi-
ated by E-CD (28). In our 6 cases of mesothelioma, E-CD stain-
ing was mainly localized to papillary clusters. E-CD expres-
Fig. 5. Mesothelial cells (A, ×400) and metastatic squamous cell carcinoma of the lung (B, ×400) exhibit diffuse strong membranous/cyto-
plasmic staining for CK5/6.
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sion may indicate particular subtypes of tumor. E-CD expres-
sion has been noted in ductal breast carcinoma, but not in lobu-
lar carcinoma (29). Among various renal epithelial neoplasia,
diffuse and strong expression of E-CD has been known to be
unique for chromophobe renal carcinoma and oncocytoma (30).
CK5/6 seems to have some limitation as a positive mark-
er for epithelial mesothelioma. In this study, CK5/6 stained
about 25% of adenocarcinomas including ovarian carcinoma,
which is often difficult to differentiate from mesothelioma. It
also stained squamous and adenosquamous carcinomas. It has
been known that most urothelial carcinomas express CK5/6,
too. CK5/6 does not distinguish mesotheliomas from reac-
tive mesothelial hyperplasias. HCK expression was similar-
ly distributed among tumor types, with higher sensitivity
for detecting squamous differentiation than CK5/6.
In contrast to both CK5/6 and HCK, CK17 was a nega-
tive marker for mesothelial proliferation. According to the
study by Miettinen et al. (17), CK17 may stain normal myoep-
ithelial and basal cells of complex epithelia, some hair shaft
epithelia, and a wide range of carcinomas, including squamous
cell carcinoma, and adenocarcinomas with complex glandu-
lar differentiation. In this study, CK17 stained none of reac-
tive or neoplastic mesothelial proliferation. Therefore, CK17
may be used as a positive marker for metastatic carcinoma
in effusion cytology, especially for carcinoma with squamous
or complex glandular differentiation, but a marker with rel-
atively low sensitivity. As already indicated in the previous
report (17), CK17 stain may also be useful for separating mam-
mary ductal carcinoma from lobular carcinoma, just like E-
CD, as well as for separating gastric adenocarcinoma from col-
orectal adenocarcinoma. 
As demonstrated by previous reports on tissue sections (31,
32), a combined CK7 and CK20 profile seems to be useful
to identify the origin of tumor cells in effusions as an adjunct
to clinical information and morphological study, mostly due
to the fact that CK20 is very specific for metastatic gastroin-
testinal and ovarian mucinous adenocarcinomas (33, 34). 
In summary, E-CD expression which is frequently hetero-
geneous in metastatic carcinoma, may be a useful positive
marker for metastatic carcinomas in effusion cytology, but
one needs to be cautious about its possible expression in meso-
thelioma. CK17 and CK20 may be negative markers for reac-
tive or neoplastic mesothelial cells while CK5/6 and HCK
may be positive markers. Any positive staining among CK5/6,
HCK, and CK17 may be noted in metastatic carcinomas with
squamous and/or complex glandular epithelial differentiation.
CK20-positive staining seems to be restricted to metastatic
adenocarcinomas from the gastrointestinal tract and ovary,
as well as among other sites of origin.
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